These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 122657)

  • 1. Penicillamine treatment of rheumatoid arthritis: relationship of proteinuria and autoantibodies to immune status.
    Zilko PJ; Dawkins RL; Cohen ML
    Proc R Soc Med; 1977; 70 Suppl 3(Suppl 3):118-22. PubMed ID: 122657
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Penicillamine compared to previous chrysotherapy in rheumatoid arthritis.
    Stein HB; Ruedy J; Atkins CJ; Offer RC
    J Rheumatol; 1983 Apr; 10(2):319-22. PubMed ID: 6864688
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The relationship between D-penicillamine--induced proteinuria and prior gold nephropathy.
    Billingsley LM; Stevens MB
    Johns Hopkins Med J; 1981 Feb; 148(2):64-7. PubMed ID: 7206401
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Proteinuria in D-penicillamine-treated rheumatoid arthritis.
    Crawhall JC
    J Rheumatol Suppl; 1981; 7():161-3. PubMed ID: 6939879
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The side effects of penicillamine therapy in rheumatoid arthritis.
    Huskisson EC
    J Rheumatol Suppl; 1981; 7():146-8. PubMed ID: 6939876
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genetic markers in rheumatoid arthritis relationship to toxicity from D-penicillamine.
    Stockman A; Zilko PJ; Major GA; Tait BD; Property DN; Mathews JD; Hannah MC; McCluskey J; Muirden KD
    J Rheumatol; 1986 Apr; 13(2):269-73. PubMed ID: 3459889
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Penicillamine nephropathy in rheumatoid arthritis. A clinical, pathological and immunological study.
    Bacon PA; Tribe CR; Mackenzie JC; Verrier-Jones J; Cumming RH; Amer B
    Q J Med; 1976 Oct; 45(180):661-84. PubMed ID: 1005658
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Longterm followup of treatment with D-penicillamine for rheumatoid arthritis: effectivity and toxicity in relation to HLA antigens.
    Moens HJ; Ament BJ; Feltkamp BW; van der Korst JK
    J Rheumatol; 1987 Dec; 14(6):1115-9. PubMed ID: 3437418
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Drug-induced anticentromere antibody?
    Haberhauer G; Bröll H
    Z Rheumatol; 1989; 48(2):99-100. PubMed ID: 2786663
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An assessment of penicillamine therapy in rheumatoid arthritis and the influence of previous gold therapy.
    Webley M; Coomes EN
    J Rheumatol; 1979; 6(1):20-4. PubMed ID: 439106
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Frequent induction of insulin autoantibodies by D-penicillamine in patients with rheumatoid arthritis.
    Vardi P; Brik R; Barzilai D; Lorber M; Scharf Y
    J Rheumatol; 1992 Oct; 19(10):1527-30. PubMed ID: 1464863
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Autoantibody formation in D-penicillamine-treated rheumatoid arthritis.
    Camus JP; Homberg JC; Crouzet J; Mery C; Delrieu F; Massias P; Abuaf N
    J Rheumatol Suppl; 1981; 7():80-3. PubMed ID: 6939887
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Tissue autoantibodies during therapy with levamisole for rheumatoid arthritis].
    Cozzi F; Ruffatti A; Dalla Santa G; Dal Molin I; Fiocco U; Todesco S
    Boll Soc Ital Biol Sper; 1982 Apr; 58(7):407-11. PubMed ID: 6979345
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Factors affecting the development of penicillamine side-effects.
    Corke CF; Huskisson EC
    Rheumatol Rehabil; 1978 Feb; 17(1):34-7. PubMed ID: 310574
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HLA-DR antigens and proteinuria induced by aurothioglucose and D-penicillamine in patients with rheumatoid arthritis.
    Speerstra F; Reekers P; van de Putte LB; Vandenbroucke JP; Rasker JJ; de Rooij DJ
    J Rheumatol; 1983 Dec; 10(6):948-53. PubMed ID: 6420562
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of D-penicillamine on inflammatory and immune reactions.
    Harth M; Keown PA; Orange JF
    Clin Invest Med; 1984; 7(1):45-51. PubMed ID: 6723124
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Autoimmune phenomena in D-penicillamine therapy].
    Kolarz G; Ludwig H; Sabeti M; Scherak O
    Acta Med Austriaca; 1975; 2(4):130-3. PubMed ID: 1083615
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of D-penicillamine on circulating protein complexes in rheumatoid arthritis and primary biliary cirrhosis.
    Wollheim FA
    J Rheumatol Suppl; 1981; 7():74-9. PubMed ID: 7014877
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Changes in various humoral immunity indicators during the treatment of rheumatoid arthritis with D-penicillamine (cuprenil)].
    Chwalińska-Sadowska H; Małdykowa H; Zajaczek-Grabowska A; Dratwianka B; Abgarowicz-Miłkowska T; Swierczyńska Z; Orłowska G; Rdułtowska H; Luft S; Rogozińska E
    Reumatologia; 1981; 19(2):151-7. PubMed ID: 6459630
    [No Abstract]   [Full Text] [Related]  

  • 20. [Early recognition of adverse effects, especially of kidney lesions, in patients with progressive chronic polyarthritis under D-Penicillamine therapy].
    Otto W; Pietruschka WD; Beenken O
    Z Gesamte Inn Med; 1975 Aug; 30(15):507-9. PubMed ID: 1189496
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.